Mumbai pharma maker of branded generics (Electral, Zifi, Enerzal), APIs, sold across 50+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 |
| Reserves | 1.5k | 1.7k | 1.9k | 2.0k | 2.1k | 2.3k | 2.4k | 2.5k |
| Borrowings | 15 | 15 | 32 | 28 | 21 | 21 | 21 | 15 |
| Other Liabilities | 250 | 208 | 281 | 333 | 350 | 412 | 433 | 418 |
| Total Liabilities | 1.8k | 2.0k | 2.3k | 2.3k | 2.5k | 2.7k | 2.9k | 2.9k |
| AssetsFixed Assets | 674 | 689 | 705 | 699 | 680 | 852 | 842 | 1.0k |
| CWIP | 24 | 19 | 105 | 198 | 261 | 137 | 163 | 96 |
| Investments | 665 | 790 | 886 | 806 | 843 | 1.0k | 1.0k | 1.0k |
| Other Assets | 451 | 458 | 575 | 640 | 684 | 698 | 874 | 775 |
| Total Assets | 1.8k | 2.0k | 2.3k | 2.3k | 2.5k | 2.7k | 2.9k | 2.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 112 | 250 | 207 | 162 | 155 | 221 | 318 | 200 |
| Cash from Investing | -121 | -98 | -77 | -145 | 11 | -17 | -199 | -110 |
| Cash from Financing | 0 | -142 | -129 | -10 | -180 | -202 | -92 | -93 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 70 | 247 | 148 | 35 | 47 | 151 | 227 | 40 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (24.0×) and current (23.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 12.8% growth and a 24× exit, ₹413 only delivers your return if you pay ₹330. The price is currently baking in 17% growth.
EPS grows 12.8%/yr for 5 years, then fades to 6% over 2, exits at 24×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 12.8% | 19.49 |
| FY28 | 12.8% | 21.99 |
| FY29 | 12.8% | 24.80 |
| FY30 | 12.8% | 27.98 |
| FY31 | 12.8% | 31.56 |
| FY32 | 9.4% ·fade | 34.52 |
| FY33 | 6.0% ·fade | 36.59 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.